News | March 25, 2026
Siemens Healthineers expands radiotherapy beyond cancer, targets osteoarthritis pain
The radiotherapy systems include TrueBeam, TrueBeam STx, VitalBeam, and Edge
The radiotherapy systems include TrueBeam, TrueBeam STx, VitalBeam, and Edge
ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025
The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials
The BEAR Implant is the first sports medicine device to carry a label claim related to lowering PTOA risk
Preclinical studies show that 4P004 modulates multiple biological markers across the joint, potentially slowing structural damage while improving function
Retatrutide, tested at 9 mg and 12 mg doses alongside diet and exercise, met all primary and key secondary endpoints
The launch of the study was on the occasion of the International Day of Persons with Disabilities
Call it a ray of hope for those enduring the pain of knee osteoarthritis -- the most common form of arthritis, affecting over 300 million people worldwide
Tofacitinib extended-release tablets are a Janus kinase inhibitor indicated for Rheumatoid Arthritis
Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions
Subscribe To Our Newsletter & Stay Updated
